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Abstract
Research on the obligate intracellular bacterium Chlamydia trachomatis demands culture in
cell-lines, but the adaptive process behind the in vivo to in vitro transition is not understood.
We assessed the genomic and transcriptomic dynamics underlying C. trachomatis in vitro
adaptation of strains representing the three disease groups (ocular, epithelial-genital and
lymphogranuloma venereum) propagated in epithelial cells over multiple passages. We
found genetic features potentially underlying phase variation mechanisms mediating the
regulation of a lipid A biosynthesis enzyme (CT533/LpxC), and the functionality of the cyto-
toxin (CT166) through an ON/OFF mechanism. We detected inactivating mutations in
CT713/porB, a scenario suggesting metabolic adaptation to the available carbon source.
CT135 was inactivated in a tropism-specific manner, with CT135-negative clones emerging
for all epithelial-genital populations (but not for LGV and ocular populations) and rapidly
increasing in frequency (~23%mutants per10 passages). RNA-sequencing analyses
revealed that a deletion event involving CT135 impacted the expression of multiple viru-
lence factors, namely effectors known to play a role in the C. trachomatis host-cell invasion
or subversion (e.g., CT456/Tarp, CT694, CT875/TepP and CT868/ChlaDub1). This reflects
a scenario of attenuation of C. trachomatis virulence in vitro, which may take place indepen-
dently or in a cumulative fashion with the also observed down-regulation of plasmid-related
virulence factors. This issue may be relevant on behalf of the recent advances in Chlamydia
mutagenesis and transformation where culture propagation for selecting mutants/transfor-
mants is mandatory. Finally, there was an increase in the growth rate for all strains, reflect-
ing gradual fitness enhancement over time. In general, these data shed light on the
adaptive process underlying the C. trachomatis in vivo to in vitro transition, and indicates
that it would be prudent to restrict culture propagation to minimal passages and check the
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status of the CT135 genotype in order to avoid the selection of CT135-negative mutants,
likely originating less virulent strains.
Introduction
Experimental evolution studies have exploited several organisms’ traits to obtain a real-time
window on evolutionary processes, to reveal new genetic targets of selection and, in general, to
get insight on the genome-scale dynamics of natural selection within microbial populations,
constituting a rare opportunity to deeply uncover the correlation (or lack of such) between
genetic and phenotypic signatures [1–3]. In bacteria, common findings include the detection of
genes or mutations underlying phenotypic alterations typically observed in laboratory evolving
bacterial populations, such as: evolution of new (or loss of) metabolic capabilities, development
of antibiotic resistance or sensitivity, or loss of virulence (namely, reduction of the infective
capacity) [1, 3–9]. For the latter alteration, it has been also observed that: i) in vitro-cultured
microorganisms are in general less virulent than the corresponding wild-types; ii) virulence
decreases gradually during in vitro culture; and iii) virulence can eventually be restored by in
vivo passage [10–14]. These features have consequently been explored by researchers in order
to enlighten pathogenic mechanisms underlying the process of infection, and also uncover new
virulence genes. Indeed, loss of function of virulence factors may be possibly related to their
dispensability in the in vitro environment, reinforcing the assumption that these genes may
play an essential and specific role in vivo.
Few studies have evaluated the impact of laboratory propagation on the population dynam-
ics of obligate intracellular bacteria [15–19], wherein the evolutionary process is ruled by the
interaction with the host. In this regard, the use of laboratory-passaged strains has been fre-
quently questioned when studying Chlamydia, including the major human pathogen C. tracho-
matis [17, 19, 20–24], which are organisms displaying a highly specialized capacity of
adaptation to the intracellular life-style. Indeed, these obligate intracellular bacteria have a
unique biphasic developmental cycle alternating between an infectious form, the elementary
body (EB), and a noninfectious replicating form, the reticulate body (RB). Shortly after enter-
ing the target eukaryotic cells, EBs differentiate into RBs, which replicate within a membrane-
bound parasitophorous vacuole termed the “inclusion”, until the newly formed infectious EBs
are released to infect neighboring cells. C. trachomatis exploits the host cell throughout all
developmental cycle by subverting critical cellular functions (such as, cytokinesis, apoptosis,
host cytoskeleton, nutrient transport, membrane trafficking pathways or immune responses)
[25–28] essentially by effector proteins translocated into the host cytosol or localized into the
inclusion membrane (Inc proteins) [29–31]. The majority of the C. trachomatis effectors and
Incs described so far were found to be transported by using a type III secretion (T3S) system
[29, 31–38]. Despite the high degree of genomic conservation in both the 1Mb chromosome
and the virulence regulator 7.5 kb plasmid, strains from different C. trachomatis serovars typi-
cally present dissimilar tissue tropism, disease outcomes and clinical prevalence. In fact, sero-
vars A-C are normally associated with ocular infections leading to blinding trachoma, strains
from serovars D-K are the major cause of bacterial sexually transmitted infections (where sero-
var E is the most clinically prevalent followed by F), and strains from serovars L1-L3 are the
causative agents of typical bubonic lymphogranuloma venereum (LGV) or the LGV-associated
proctitis [39–41] (the latter is primarily caused by L2b strains [42]).
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In a previous approach to study the in vitro population dynamics for this bacterium [15],
we observed that culture propagation yielded discreet genomic changes in the absence of spe-
cific selective pressures. Despite the advance of culture-independent C. trachomatis genome
sequencing [22, 43–45], our data suggest that the in vivo-derived genetic make-up is not
strongly compromised during the classical culture procedures for propagating C. trachomatis.
However, this discreet scenario of genomic alterations may strongly impact gene expression
and virulence. Indeed, we detected that clones carrying an inactivated version of the recently
identified virulence gene CT135 (which is believed to function in sustaining a more persistent
or chronic infections in vivo [46, 47]), became 100% frequent in the population of an epithe-
lial-genital strain [15]. Furthermore, assessing the impact of introducing C. trachomatis in vitro
gains special relevance in light of the recent rampant development of transformation and gene
knockout experiments in C. trachomatis, which demand culture propagation [48–52]. Thus, it
is crucial to well characterize the C. trachomatis in vivo to in vitro transition process in order to
avoid bias in the interpretation of downstreammutagenesis-derived data and also because viru-
lence of propagated strains may be attenuated. We now performed an experimental evolution
study over C. trachomatis strains from serovars displaying dissimilar clinical prevalence and
representing the three disease groups. We evaluated the dynamics by which mutations appear
and their frequency in the evolving bacterial populations through whole-population sequenc-
ing at various time-points after C. trachomatis introduction in vitro. We also investigated tran-
scriptome alterations throughout adaptation. Specifically, we aimed to answer the following
questions concerning the in vitro adaptation of C. trachomatis: i) is the duration of bacterial
developmental cycle affected?; ii) is the adaptive dynamics dependent on the tissue-specificity
or disease outcomes of the infecting strains?; iii) which are the genomic and transcriptomic
events underlying adaptation?; and iv) is there parallelism in the adaptive outcomes across
strains?
Materials and Methods
Chlamydia trachomatis strains
Six C. trachomatis strains belonging to the three disease groups (one ocular strain, four epithe-
lial-genital strains and one strain associated with LGV-proctitis) were used in the present
study. The ompA genotype was verified for all strains, as previously described [53]. The ocular
strain C/TW-3 was isolated from the human conjunctiva and was obtained from the American
Type Culture Collection (ATCC VR-1477). The remaining strains belong to the culture collec-
tion of the Portuguese National Institute of Health. The epithelial-genital clinical isolate Ia/
CS190/96 was isolated from a male urethra, whereas the epithelial-genital D/CS637/11, F/
CS847/08 and E/CS1025/11 were collected from swabs of the cervix of women with no symp-
toms, HPV-associated warts, and no available clinical data, respectively. Finally, the LGV strain
L2b/CS19/08 was isolated from a anorectal swab of a 29-years old HIV(+) man with proctitis
and syphilis.
C. trachomatis in vitro propagation and preparation for whole-population
full-genome sequencing
Each clinical specimen (swabs) in transport medium (2 sucrose phosphate buffer supple-
mented with gentamicin, vancomycin and nistatin) or the ATCC inocula (for the C/TW-3
strain) was inoculated in HeLa229 confluent monolayers (cultured on 24-well plates in MEM
containing 10% fetal bovine serum, 5 mM L-glutamic acid, 10 μg/ml gentamicin and 0.5 μg/ml
fungizone at 37°C, 5% CO2) by centrifuging at 2110 rcf for 1h at 34°C [54]. The cultures were
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then incubated for 1h at 37°C, 5% CO2, and the cell medium was subsequently replaced by
fresh medium supplemented with vitamins (1x), non-essential aminoacids (1x), glucose (0.5%)
and cycloheximide (0.5 μg/ml) (so called “enriched medium”). Cultures were allowed to grow
at 37°C, 5% CO2. At the end of the bacterial developmental cycle, the infected cells were har-
vested using glass beads and disrupted through sonication (Vibra Cell, Bioblock Scientific),
and further submitted to low-speed centrifugation (100 rcf for 7min). The bacterial-enriched
supernatant was collected and re-inoculated by centrifugation (835 rcf for 1h) onto new
HeLa229 confluent monolayers (first passage). Each chlamydial culture was continuously pas-
saged in T25 cm2 flasks, so the passage numbers for the clinical isolates refer to the total num-
ber of passages after inoculating the content of the clinical swab. Inoculations were always
preceded by sonication followed by low-speed centrifugation, so that the bacterial life-cycle
was continuously synchronized. The volume of transferred inocula ranged from 1/10 to 1/2 of
the total suspension of the previous passage (depending on the bacterial-enrichment), limiting
drift and random selection of clones derived from bottlenecks. Strains D/CS637/11, E/CS1025/
11, F/CS847/08 and L2b/CS19/08 were propagated over 30 in vitro passages, whereas strains
Ia/CS190/96 and C/TW-3 were propagated until the passage 100. The propagation extension
of these two strains relied on the need either to clarify the evolutionary scenario that was being
observed (for the former) or to obtain a long-term adaptive landscape for an ocular strain (for
the latter), mirroring previous data for one LGV and one epithelial-genital strain [15]. Passages
~6, 20, 30, 50 and 100 were selected for whole-population full-genome sequencing (see below),
where culture scale-up to obtain enough DNA for sequencing was performed two or three pas-
sages before each time-point. The contents of these flasks was harvested and further subjected
to a discontinuous density gradient purification procedure, before proceeding with DNA
extraction and quantification as previously described [15].
Whole-population full-genome sequencing
DNA samples were used to prepare Illumina paired-end libraries according to the manufac-
turer's instructions (Illumina Inc., San Diego, CA). Libraries were subsequently subjected to
cluster generation and paired-end sequencing (2x250 bp) by using the next-generation
sequencing platform Illumina MiSeq (Illumina Inc., San Diego, CA, USA), according to the
manufacturer’s instructions. FastQC (http://www.bioinformatics.babraham.ac.uk/projects/
fastqc/) and FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) tools were applied to check and
improve the quality of the raw sequence data, respectively. Reads were mapped to C. trachoma-
tis chromosome and plasmid sequences available at GenBank using both Bowtie2 [version
2.1.0 (http://bowtie-bio.sourceforge.net/bowtie2/index.shtml)] [55]. SAMtools/BCFtools
(http://samtools.sourceforge.net/) [56] were applied to call single nucleotide polymorphism
(SNPs) and insertions/deletions (indels), which were carefully confirmed through visual
inspection using the Integrative Genomics Viewer [version 2.3.12; (http://www.broadinstitute.
org/igv)] [57]. The assembled chromosome and plasmid sequences obtained from the first
time-point were used to map the reads generated from subsequent time-points. The frequency
of the mutations in the population at the time of sampling were carefully scrutinized through
IGV inspection. The mutations reported were supported by a depth of coverage above 150x, a
score of quality above 20 for more than 90% of the bases sustaining each polymorphism and a
relative percentage of reads mapping to either of the two DNA strands (strand bias) ranging
from 40 to 60%. We also inferred the plasmid copy number per chromosome throughout the
different time-points, based on the ratio plasmid/chromosome taken from the respective depth
coverage. Chromosome and plasmid sequences obtained at the first time-point were annotated
by the NCBI Prokaryotic Genomes Annotation Pipeline 2.3 and deposited in GenBank (see
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accession numbers in the S1 Table). For the global evaluation of the whole genomic backbone
of the studied C. trachomatis genomes, we compared them with the ones from 52 previously
sequenced C. trachomatis strains [58], as described elsewhere [59].
Impact of in vitro passaging on the C. trachomatis growth rate
The growth rate (and doubling times) of bacterial populations was measured at the initial and
final stages of the evolution experiment in order to assess the impact of in vitro propagation on
the bacterial fitness (i.e., the ratio of growth rates of evolved population relative to its ancestral).
Briefly, for each bacterial population, HeLa229 confluent monolayers on 6-well plates were
inoculated (by centrifuging at 2110 rcf for 1h at 34°C) at a multiplicity of infection of about 1
with fresh inocula obtained from the cultures (in T25 cm2 flasks) under passaging. Cells were
harvested for DNA extraction at 4, 10, 20 hours post-infection and at the end of the bacterial
life-cycle (ensuring that cell lysis had not occurred). DNA samples were then used to quantify
the number of C. trachomatis genomes at each time-point through real-time quantitative PCR
(qPCR), as previously described [15]. The growth rate and doubling times (dt) were calculated
using the standard formulas: growth rate = (lnN1 –ln N0) / t (1–0) and dt = (t1 –t0)/n, where
(t1—t0) is the time elapsed during the period of higher growth and n is the number of bacterial
generations. The n was calculated based on the formula: n = (log10N1/N0)/log102, where N1
and N0 are the genome copy numbers determined at the defined time-points.
Yield of infectious progeny of the serovar D CT135-positive and
CT135-negative isolates in cell culture
In order to complement the data from growth rate assays and to obtain an alternative perspec-
tive of the impact of the in vitro propagation on the chlamydial replicating capacity, we further
evaluated the yields of inclusion-forming units (IFUs) (as a measure of progeny) of the serovar
D clinical isolate at beginning of the experiment (here designated as “CT135-positive”) and
after CT135 loss (here designated solely as “CT135-negative”, although the two flanking genes
were also partially deleted). We grew both the D/CS637/11 CT135-positive and CT135-nega-
tive strains in HeLa229 cells, and used serial dilution titration to determine the IFU permillili-
ter of the EB-enriched stocks. Briefly, serial dilutions were inoculated as above in HeLa229
monolayers seeded on 96-well plates, the cells were fixed at 22 h post-infection with methanol,
stained with an anti–C. trachomatis lipopolysaccharide antibody (Pathfinder), and the inclu-
sions were enumerated by immunofluorescence microscopy. Inocula of equivalent concentra-
tion (IFU permiliter) for both the ancestral and the evolved strain were then applied to infect
HeLa229 monolayers (on 6-well plates) at a MOI of 1. At the time-points 6, 12, 18, 24, 30, 36,
42 and 48 post-infection, the cultures were harvested and followed the same procedure of serial
dilution titration for inclusion counting and further construction of one-step growth curves.
These curves were also important to define the proper time-points to be used in transcriptome
(RNA-seq) assays.
Evaluation of molecular stability of CT135 transcripts
The molecular stability of the bacterial transcripts is traditionally evaluated throughout the
quantification of the mRNA half-life time after transcriptional blockage with the antibiotic
rifampicin [60, 61], which inhibits the de novo synthesis of RNA. Since the quick degradation
of mRNAs from genes that are deleterious in a given environment is believed to confer selective
evolutionary advantage [62], we sought to evaluate the molecular stability of CT135 transcripts
before and after the spread of CT135-negative clones. We performed this assay for the clinical
isolates with emergent CT135-negative clones. After a preliminary optimization stage, we
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opted to use a final rifampicin concentration of 10 μg/ml (Sigma-Aldrich) since it allowed a
maximum bacterial transcriptional arrest while causing no visible morphologic effects on
HeLa229 cells (data not shown). This concentration is in agreement with the one used in a pre-
vious study aiming to assess the molecular stability of transcripts in other Chlamydia species
[61]. For the assays to determine CT135 mRNA half-life time, fresh EB-enriched inocula from
each isolate under passaging (for both ancestral and evolved populations) were inoculated as
above on 6-well plates, and cultures were allowed to grow until antibiotic treatment. Consider-
ing that higher levels of CT135 transcripts are detected at early stages of the C. trachomatis life-
cycle [32, 63], we opted to evaluate the molecular stability of the CT135 transcripts at this
stage. Hence, at 4h pi, the culture medium was replaced by fresh medium containing rifampicin
and after 10 min cells were scraped with PBS and mechanically disrupted by sonication. The
final suspension was rigorously divided into two identical aliquots and immediately frozen in
liquid N2. Culture samples were similarly harvested before rifampicin addition (at 4h pi). The
twin aliquots were submitted to independent DNA and RNA extraction using QIAamp DNA
Mini Kit (Qiagen) and RNeasy Mini Kit (Qiagen), respectively, according to manufacturer's
instructions. Purified RNA samples were further subjected to cDNA generation using TaqMan
Reverse Transcription (RT) Reagents (Applied Biosystems, Life Technologies, Branchburg, NJ,
USA), as previously described [64]. cDNA samples were used to quantify the transcript’s level
through qPCR before and after rifampicin treatment. In order to overcome putative bias asso-
ciated with differential degradation along the operon, we applied two independent qPCRs tar-
geting the two genes (CT134 and CT135) [46], and calculated a mean value. The mRNA levels
were normalized against the number of C. trachomatis genomes quantified on the correspond-
ing DNA samples, using a previously described qPCR [65]. All quantifications were performed
using a LightCycler 480 (LC480) Instrument (Roche). The reagents consisted of LightCycler
480 SYBR Green I Master (Roche), 400 nM of each primer and 5 μl of sample DNA or cDNA,
in a final volume of 25 μl. The sequences of all primers used in this study are listed in the S2
Table. The mRNA half-life times (t ½) were calculated by using an adaptation of the “two-fold”
decay step method [66] based on the fit of an exponential decay between values obtained at the
first time-point (before rifampicin addition) (N0) and the values calculated tminutes (10 min)
after the transcriptional arrest (N1), using the formula: t ½ = -ln2/k; where the rate of decay
rate (k) was estimated as follows: k = ln(N1/N0)/ t.
Evaluation of the impact of a deletion event involving CT135 on C.
trachomatis transcriptome
Analyses of global gene expression in C. trachomatis through microarrays or RNA-seq have
been almost exclusively performed at mid-stage of the developmental cycle in order to ensure
the detection of transcripts from a higher number of genes [51, 63, 67–69]. Here, we also
focused on the bacterial mid-cycle, and chose the time-point for RNA-seq differential expres-
sion analysis according to the distinct growth dynamics observed for the D/CS637/11
CT135-positive and CT135-negative isolates (evaluated by IFU-based growth curves) (see
Results section). Hence, HeLa229 confluent monolayers (cultured on T25 cm2 flasks) were
infected with serovar D CT135-positive (passage 7) and CT135-negative (passage 20) isolates
at a MOI of about 1 (as described above), and were grown for 30 h and 24 h post-infection,
respectively. Subsequently, the culture medium was discarded, cells were harvested using 2:1
volumes of RNAprotect bacteria reagent (Qiagen, Valencia, CA), sonicated, and subsequently
centrifuged at 100 rcf for 7 min. The supernatant was collected, pelleted by centrifugation
(18500 rcf for 15 min) and further processed for RNA extraction using the RNeasy Mini Kit
(Qiagen), according to manufacturer's instructions. Samples were treated on column with
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RNase-free DNase (Qiagen), and RNA samples were subjected to Agilent Bioanalyser (Agilent
Technologies) analyses before and after the bacterial mRNA enrichment using MICROBEnrich
(Ambion, Austin, Texas) and MICROBExpress (Ambion) protocols, according to manufactur-
er’s instructions. Bacterial mRNA-enriched samples were further subjected to library construc-
tion (TruSeq Stranded mRNA sample preparation kit, Illumina) and sequencing on an
Illumina MiSeq sequencer using a paired-end (2x150bp) strategy (about 15M reads were dedi-
cated per sample). The quality of the raw sequence data was assessed through FastQC analysis.
The sequence reads were mapped (using Bowtie2) to the D/CS637/11 genome (sequenced in
this study) and the expression of each chromosome and plasmid coding sequence (CDS) was
normalized as fragments per kilobase of CDS permillion mapped reads (FPKM) using the Cuf-
flinks (version 2.1.1; http://cufflinks.cbcb.umd.edu/). In order to overcome the variable effi-
ciency of the mRNA enrichment step across samples and to improve the overall robustness of
transcript abundance estimates, reads from bacterial rRNA and tRNA were selectively masked
in the analyses. Differential gene expression analyses between D/CT135-positive and D/
CT135-negative strains were conducted using Cuffdiff, where FPKMs and fragment counts are
scaled taking the median of the geometric means of fragment counts across all libraries (geo-
metric normalization method). This rationale is identical to the one used by DEseq [70]. The
Benjamini–Hochberg procedure, which controls the false discovery rate (FDR), was applied to
adjust raw P-values for multiple testing [71]. Genes were considered to be differentially
expressed when the fold change of expression exceeds the two-fold and the adjusted P-values
were<0.05. RT-qPCR validation of the RNA-seq results was performed on a LC480 apparatus
(as described above) using cDNA samples obtained from total RNA aliquots collected before
depletion of rRNA and polyadenylated mRNAs. RT-qPCR data for each gene were normalized
against the data obtained for the 16S rRNA transcript. Differential expression data are based
on two biological replicates. In order to ensure that the observed expression differences were
due specifically to the deletion event involving CT135 and not to other factors underlying labo-
ratory propagation, we performed a control RNA-seq experiment by analysing the Ia/CS190/
96 isolate within the same time frame as for the serovar D strain. This shows up as a suitable
control, since this strain did not reveal any mutation in the entire genome throughout the same
passaging period (i.e., until passage 20).
Results
The genome make-up of studied strains represents the major branches
of the species tree
We performed experimental evolution of C. trachomatis ocular (C/TW-3; an historical proto-
type strain), epithelial-genital (D/CS637/11, E/CS1025/11, F/CS847/08 and Ia/CS190/96; clini-
cal isolates) and LGV (L2b/CS19/08; an anorectal isolate associated with LGV-proctitis)
strains. Among these, we recently described the genomes of C/TW-3 [72] and L2b/CS19/08
[54]. To integrate the genetic backbone of all strains used in this work in the frame of the
known species phylogeny and diversity [58], we first determined and analyzed the genome of
the strains after minimal passages. We observed the phylogenetic segregation of each genome
within the four major branches of the species tree, where each strain clustered with the other C.
trachomatis strains sharing not only the tissue-specificity but also the clinical prevalence of the
corresponding serovars (S1 Fig). Of note, two strains (Ia/CS190/96 and F/CS847/08) revealed
clear traces of recombination involving epithelial-genital strains (S1 Fig), similarly to what has
been extensively described [58, 73, 74]. Globally, the present study aiming to evaluate the
dynamics underlying the in vivo to in vitro transition of C. trachomatis involves strains
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representing, not only the three disease groups (ocular, epithelial-genital and LGV), but also
the four major genetic branches of the species tree.
Initial populations reveal some degree of allelic variation
Genomic analyses of the initial populations revealed phenomena associated with heterogeneity
within DNA homopolymeric tracts located in the gene encoding the cytotoxin (CT166) and
upstream from the gene CT533/lpxC, which encodes an essential enzyme [UDP-3-O-(R-
3-hydroxymyristoyl)-GlcNAc deacetylase] in the biosynthesis of lipid A [75, 76]. Cytotoxin
will be focused on the next section as the detected variability may underlie its functionality.
Regarding the CT533/lpxC, for strain E/CS1025/11 we found a homopolymeric tract 36 bp
upstream from the start codon (between the predicted -35 and -10 TATA boxes) with a string
of 12 ‘A’ in 87% of the reads and 11 ‘A’ in 9% of the reads (4% for other ‘A’ counts) (Fig 1A and
1B). Although a similar scenario was also observed for initial populations of the other strains,
we drew attention to E/CS1025/11, since we detected a progressive increment of the 11 poly(A)
tract throughout bacterial propagation (Fig 1A and S3 Table). Besides homopolymeric tracts,
strains Ia/CS190/96 and L2b/CS19/08 revealed no mixture of clones, whereas the D/CS637/11,
F/CS847/08 and C/TW-3 revealed allelic mixtures (S3 Table). For the serovar D strain, the
clones in the population are distinguished by two non-synonymous nucleotide polymorphisms
(‘GC’$ ‘AA’) affecting the same codon in the gene CT633/hemB, which encodes an enzyme
(delta-aminolevulinic acid dehydratase) involved in the heme biosynthesis [77]. A recent study
showed that the heme metabolism is important for C. trachomatis infectivity [78], and, in
Fig 1. Phase variation mediated by variable homopolymeric tracts. Panel A. The graph shows the evolution throughout passaging of the percentage of
sequence reads with different ‘A’ counts in the homopolymeric tract upstream from CT533/lpxC for the strain E/CS1025/11. The poly(A) tract corresponds to
poly(T) in the annotated leading strand. Panel B. Schematic view of the putative promoter region of CT533/lpxC. The predicted transcription start site [126] is
labeled by +1. The variable poly(A) tract (in bold) falls between the predicted -35 and -10 hexamers (underlined). BLAST analyses revealed the existence of
variable number of ‘A’ counts inC. trachomatis genomes, and also that the nucleotide indicated with an arrow is deleted exclusively in all LGV strains. Panel
C. The graph shows the percentage of sequence reads with different ‘G’ counts in the variable homopolymeric tract of CT166 found in the initial populations
of the epithelial-genital strains. “G” counts of nine correspond to an “ON” protein. Panel D. Schematic view of the four positions (numbers 1 to 4) relative to a
gene at which contingency loci (e.g., homopolymeric tracts) can cause phase variation (adapted from van der Woude MW and Bäumler AJ, Clin Microbiol
Rev 17:581–611, 2004 [152]). Whereas positions 1 and 2 are associated with transcription initiation and position 4 with translation (ON/OFF), the mechanism
regarding the position 3 is not completely disclosed. We found heterogeneity in length within homopolymeric tracts located in positions 2 (for CT533/lpxC)
(blue), 3 (for CT043/slc1 and the operon CT134-CT135), and 4 (for CT166—cytotoxin) (red).
doi:10.1371/journal.pone.0133420.g001
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Staphylococcus aureus, it is known that hemBmutants display increased ability to persist intra-
cellularly [79]. For the serovar F clinical isolate, the mixture of clones was found to involve a
silent mutation in the CT682/pbpB gene. This gene codes for a penicillin binding protein that
play a role in the final stages of the synthesis of peptidoglycan, which was recently discovered
in Chlamydia [80]. Corroborating the assumption that this mixture of clones comes from the
in vivo population, there are C. trachomatis pbpB sequences in GenBank supporting both
nucleotide variants. Finally, concerning the ocular prototype strain C/TW-3, the initial popula-
tion contained a mixture of CT135-positive and CT135-negative clones, where the minor fre-
quent clones carry one inactivating indel in the gene CT135 (S3 Table). Globally, allelic
mixtures were sustained by depth of coverage ranging from ~180x to ~1100x (S1 Table).
Phase variation may underlie functionality of C. trachomatis cytotoxin
The C. trachomatis cytotoxin is a putative effector protein believed to act on the rapid disas-
sembly of cytoskeleton actin filaments during the bacterial internalization process and to cause
a cytopathic effect in host cells [81–84]. Contrarily to epithelial-genital strains, LGV and oculo-
tropic strains do not encode a functional cytotoxin [81, 85]. Intriguingly, we found clones in
the initial populations of all epithelial-genital isolates displaying a potentially disrupted cyto-
toxin due to an inactivating variable ‘G’ count in a poly(G) tract at the 5’-end of CT166 (gene
positions 29 to 37). In fact, although the predicted functional cytotoxin (“ON”) harbors a string
of a 9 Gs, the majority of the sequence reads generated for three epithelial-genital isolates
(>83% for D/CS637/11 and F/CS847/08, and>66% for Ia/CS190/96) carry a 10 ‘G’ homopoly-
meric tract that causes frameshift (“OFF”) (Fig 1C). This is supported by a high depth of cover-
age from 130x to 470x, and it is known that homopolymer-associated errors are highly reduced
when using the Illumina technology [86, 87], which has been used, for instance, for resequen-
cing the variable tracts of contingency loci in Campylobacter jejuni [88]. We believe that this
variability may underlie the regulation in vivo of the cytotoxin functionality through an ON/
OFF mechanism of phase variation. In fact, we performed a BLAST search and found out that
‘G’ counts other than nine are present in several recently released culture-independent C. tra-
chomatis genomes [22].
In vitro passage of C. trachomatis results in a tropism-specific loss of the
virulence gene CT135
We evaluated the emergence and spread of adaptive mutations throughout C. trachomatis
experimental evolution (Fig 2). No emergent mutations were detected for the LGV-proctitis
strain (L2b/CS19/08) at any time-point. In contrast, we observed inactivating mutations in the
virulence gene CT135 for all the epithelial-genital strains, which rapidly rose in frequency. We
estimated that, in each 10 in vitro passages of epithelial-genital strains, a mean of 23.1% (SD
±11.9) of the emergent clones will carry inactivating mutations in this virulence gene. An
extreme example stands for D/CS637/11, where CT135-negative clones reached a frequency of
100% at passage 20. For this strain, the inactivating mutation consisted of a 1452-bp deletion
between direct repeats leading to the putative formation of a fusion gene involving the flanking
genes CT134 and CT136 (Fig 3). Three major alternative mechanisms may have mediated this
event: i) intermolecular crossing over between DNA direct repeats; ii) intramolecular pairing
of repeats by looping out followed by homologous recombination; and iii) DNA polymerase
slippage during DNA replication [89–91]. Of note, deletions between direct repeats have been
proposed to have played a role in the genome reductive evolution of Chlamydia bacteria [85,
92, 93], namely in the cytotoxin loss in the ocular C. trachomatis serovars A, Ba and C [85]. In
support of the expression of the fusion protein CT134-CT136, we observed the existence of
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Fig 2. Mutational scenario throughout experimental evolution. Panel A. Chromosomal location of the
genomic alterations observed during the in vitro passaging. The chromosomal position of each mutation
(scale adjusted and given by the locus name) and the type of mutation event (inactivating events represented
in red) are shown for each strain (see also S3 Table for details). Inactivating SNPs or indels refer to events
leading to protein truncation (regardless the length of the resulting protein). For the strain D/CS637/11, the
CT135 inactivating event involved the entire gene deletion between direct repeats (Fig 3). Panel B.
Dynamics of the emergence and spread of mutations and their frequency in the evolving bacterial
populations. For each time-point (passages 5–7, 10, 20, 30, 50 and 100), circular graphs show the frequency
of the mutations in the bacterial population, where each color represents a different mutated locus. The
number of bacterial generations was estimated taking into account the minimum and maximum values of the
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transcripts (in RNA-seq) compatible with this novel genomic structure. However, immuno-
blotting attempts to detect the protein (polyclonal antibody targeting CT136) in culture lysates
obtained at mid-cycle were unsuccessful (data not shown).
In a later point of the evolution experiment, a parallel scenario of gene inactivation occurred
for CT713/porB gene for three out of four epithelial-genital strains (Fig 2 and S3 Table). Since
this parallelism provides a strong signal of metabolic adaptation of C. trachomatis to the culture
conditions, we will discuss it in detail in the next section. Some other adaptive mutations were
fixed in the evolving populations, although no parallelism across strains was observed for the
targeted genes. For the serovar E strain, we detected the emergence and evolution to predomi-
nance of clones carrying one inactivating SNP in the start codon of CT645, which encodes a
predicted integral membrane protein with unknown function (YGGT family) [77] that shows
homology to a protein (YlmG) potentially involved in cell division [94, 95]. Also, for the Ia/
CS190/96 strain, two new adaptive mutations arose: an inactivating indel for CT257 and one
non-synonymous SNP for CT205/pfkA_1, both reaching about 100% frequency. CT257 codes
for a CBS domain-containing protein [96] that was suggested to display tropism for eukaryotic
lipid-droplets [97] whereas CT205/pfkA_1 encodes a key enzyme (diphosphate-fructose-
6-phosphate 1-phosphotransferase) involved in the carbohydrate metabolism [77].
mean doubling time of the strains analyzed at each time-point, and assuming a conservative approach by
considering 15 hours of exponential phase per bacterial life-cycle (i.e, per passage). Loci designations are
based on genome annotation of the D/UW3 strain (GenBank accession number NC_000117).
doi:10.1371/journal.pone.0133420.g002
Fig 3. Schematic representation of the CT135 deletion in the serovar D strain. The inactivating event of
CT135 involved the complete gene deletion between direct repeats (in blue) and the putative formation of a
fusion gene enrolling the two flanking genes (CT134 and CT136). The underlying mechanism likely relied in
one of three major pathways: A—intermolecular crossing over between direct repeats followed by
recombination (yielding both a tandem duplication and a deletion); B—looping out in between direct repeats
followed by recombination; and C—DNA polymerase slippage during DNA replication [89–91]. The figure
also shows the position of all CT135 frameshift mutations (labeled byΨ) reported here and elsewhere [46,
48, 131, 149, 150, 164], demonstrating that the strains evolved towards CT135 inactivation regardless the
“genetic pathway” that drove that inactivation The bilobal hydrophobic domains that putatively enable the
insertion of the CT134 and CT135 proteins into the inclusion membrane [33] are highlighted in grey.
doi:10.1371/journal.pone.0133420.g003
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Regarding the ocular strain C/TW-3, we verified that the minor frequent CT135-negative
clones present in the initial population evolved to extinction, reflecting a completely opposite
scenario to the one observed for the epithelial-genital strains. Additionally, we observed the
further fixation of four adaptive mutations reaching 100% frequency at passage 100 (Fig 2 and
S3 Table). These mutations targeted the following loci: the intergenic region (IGR) upstream
from the gene CT043/slc1 (a 1-bp deletion in a poly(A) tract affecting the transcript sequence),
the genes CT189/gyrA_1 and CT664/cdsD, and a putative ORF (CTW3_00885) [72] encoding
a fragment of the ancestral Chlamydia cytotoxin. Of note, two of these mutations might have
likely interfered with T3S-mediated bacterial functions, since the gene CT043/slc1 encodes a
chaperone (Slc1) of several virulence-associated T3S effectors [98, 99], whereas the gene
CT664 encodes a forkhead associated (FHA) domains-containing protein (CdsD/YscD) pre-
dicted to form the inner membrane ring of T3S apparatus [100, 101].
Globally, the observed mutations correspond to an empirical substitution rate (we used a
conservative approach by considering minimal exponential phases) ranging from 9.86 x 10−9
to 1.89 x 10−8 mutations per base pair per generation (or 0.0103–0.0197 mutations per genome
per generation), which fits data from adaptive evolution studies in bacteria, where evolving
populations are expected to fix no more than ~2.5 mutations per 100 generations [4, 6, 102]. Of
note, no mutations were observed in plasmid sequences, and the number of plasmids per chro-
mosome did not significantly change throughout laboratory propagation (S1 Table).
Inactivating mutations in the gene CT713/porBmay reflect metabolic
adaptation to the available carbon source
Three out of the four epithelial-genital strains acquired putative inactivating mutations in
CT713/porB that increased in frequency (Fig 2 and S3 Table). CT713/porB gene codes for a
porin that specifically enables the uptake of dicarboxylates into the tricarboxylic acid (TCA)
cycle [103]. This cycle is incomplete in C. trachomatis, and requires either exogenous glutamate
(transported by the major outer membrane protein—MOMP) or 2-oxoglutarate (transported
by PorB) from the host cell [77, 103, 104]. Hence, as we supplemented the chamydial cultures
with glutamate, the 2-oxoglutarate uptake pathway might become expendable, leading to both
the inactivation of the porin-encoding gene CT713/porB and exclusive maintenance of the
TCA feeding through the glutamate pathway. This hypothesis would rely on a typical scenario
of metabolic adaptation to the available carbon source, and fits well with the postulation that
the reduction of importance of the TCA cycle metabolic pathway throughout the adaptation of
Chlamydiae to an intracellular lifestyle led to the pseudogenization of TCA cycle-related genes
[105].
The growth rate of laboratory evolving populations increased relative to
the ancestral populations leading to shorter life-cycles
In Chlamydia, fitness estimates essentially rely on evaluating the growth rates or IFU yield
rather than on capturing the phenotype by which the adaptive advantage operates, as knock-
out assays are not optimized yet for such purpose. Thus, we searched for changes in the fitness
of the evolving populations by comparing the growth rates of the strains at the beginning and
at the end of the study, a methodology largely applied in bacterial experimental evolution stud-
ies [3]. Globally, the growth rate of all evolved populations relative to their ancestors increased
from 18,3% (for E/CS1025/11) to 92,0% (for F/CS847811) (Fig 4A and 4B), reflecting the pro-
gressively shortening of the bacterial life-cycles observed through phase-contrast microscopy.
In addition, we complemented this data by constructing a one step-growth curve (i.e., enumer-
ation of IFUs over time) to assess the length of the life-cycle before and after the CT135 loss by
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Fig 4. Impact of in vitro passaging on theC. trachomatis growth kinetics. Panels A and B. Comparison
of the growth rates and doubling times between ancestral (grey) and evolved populations (black). The
percentage values above the bars correspond to the growth rate increment of the evolved population
relatively to the ancestral. Panel C. Comparison of the one-step growth curve between D/CS637/11
CT135-positive and CT135-negative strains. Cells grown in the same conditions were infected at a MOI of 1,
and cell scrapings were collected over time after infection for analysis of inclusion-forming units (IFUs). The
black line represents the evolved CT135-negative D/CS637/11 strain, whereas the grey line represents the
ancestor CT135-positive strain. The shaded area indicates the time points chosen for RNA-seq differential
expression comparative analyses.
doi:10.1371/journal.pone.0133420.g004
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the serovar D strain (Fig 4C). This assay revealed a shorter developmental cycle for the propa-
gated strain, which was also sustained by the observation of a similar fold change in the genome
copy number between 4h pi to 30h for the D/CT135-positive strain and 4h pi to 24h for the D/
CT135-negative strain (data not shown).
The genomic inactivation of CT135 in the epithelial-genital strains is
accompanied by a quick degradation of the mRNA
The mechanisms for controlling the mRNA processing and decay play an important role in the
continuous adjustment of the levels of gene expression according to the protein needs, with
bacterial mRNA half-life times ranging from seconds to hours [62, 106]. We evaluated whether
the molecular stability of CT135 transcripts was affected after protein truncation. We observed
that the mRNA half-life time decreased for the epithelial-genital isolates (Fig 5), whereas it
remained unaltered for the LGV clinical isolate. These results are concordant with an adaptive
scenario where both the genomic inactivation and mRNA processing mechanisms concomi-
tantly act to increment the competitive fitness of the CT135-negative clones. Curiously, when
looking at the mRNA half-life time of the ancestral strains, we observed that the CT135-tran-
script is more labile for the LGV strain.
Genomic deletion involving CT135 affects the expression of multiple
virulence-associated genes
The mechanism by which CT135 promotes C. trachomatis virulence is unknown. Taking into
account the rapid and parallel loss of the CT135 in all epithelial-genital strains, we wonder if
the in vitro inactivation of CT135 is beneficial likely because it reduces the expression of several
genes, and hence the associated energetic costs of unused functions. We performed RNA-seq
analyses to compare the global gene expression of the serovar D CT135-positive and
CT135-negative strains. Here, we are assuming that potential changes in gene expression are
essentially due to the CT135 loss, but the deletion of 1452-bp also partially involved the flank-
ing genes CT134 (encodes a putative Inc protein) and CT136 (encodes a Lysophospholipase
Fig 5. CT135mRNA decay analysis. Panel A shows the comparison of the relative amount of transcripts at 4 h post-infection (pi) and after 10 min of
transcriptional blockage with rifampicin (10 μg/ml) between the ancestral (grey) and the evolved populations (black). The assay was performed for all strains
with emergent CT135-negative clones (i.e., all epithelial-genital isolates) and for the strain L2b/CS19/08 (control). The number of transcripts was quantified
by independent RT-qPCR targeting the two genes of the operon CT134-CT135 (see methods for details), except for serovar D strain as the evolved
population lacks CT135. Data was normalized against the number of C. trachomatis genomes quantified on the corresponding DNA samples. In order to
facilitate the comparative analysis, the normalized value before rifampicin treatment (4h pi) was arbitrarily set to 1. Panel B shows the mRNA half-life times
calculated based on the fit of an exponential decay between the quantified values at 4h pi and the values calculated 10 minutes after the transcriptional
arrest.
doi:10.1371/journal.pone.0133420.g005
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esterase) (Fig 3), so a synergistic effect cannot be ruled out. This particularly stands for CT134,
as it is predicted to belong to the same operon as CT135 [46]. By using a false discovery rate
cutoff of 0.05 and a fold-change cutoff of>2.0, we identified 48 significantly differentially
expressed genes and one non-coding RNA, all being down-regulated in the CT135-negative
strain (Table 1 and Fig 6). To confirm these results, we used RT-qPCR to evaluate the expres-
sion of a set of the highlighted genes and found a good level of correlation (slope 1.01, Pearson
correlation 0.958, N = 7) (S2 Fig). Remarkably, the pool of genes that are down-regulated after
the occurrence of the deletion event involves multiple virulence-associated genes (some of
them belonging to the same operon) (Table 1). We highlight genes coding for: i) the most
prominent adhesins (e.g., CT443/OmcB) [107, 108] and T3S effectors (e.g., CT456/Tarp,
CT694 and CT875/TepP) known to play a role in the C. trachomatis host-cell invasion process
[109–112]; ii) multiple T3S-related proteins, such as substrates (e.g., CT082, CT619-20 and
CT847-9) [38, 99, 113–115], a chaperone (CT576/Scc2) [116] and components of the translo-
cation pore (e.g., CT578/CopB and CT579/CopD) [117]; iii) genes encoding proteins puta-
tively related to the chlamydial protease/proteasome-like activity factor (CPAF), either
potential substrates (e.g., CT005, CT288, CT443/OmcB, CT456/Tarp and CT694-5) [118–120]
or other virulence proteases acting in the same pathways in the subversion of host-cellular
functions (e.g., CT441/Tsp and CT868/ChlaDub1) [121–124]; and iv) virulence-associated
proteins regulated by the plasmid-encoded Pgp4 (e.g., CT049-CT051, CT142-CT144 and
CT798/GlgA) [51]. Regarding the latter set of genes, we looked at the differential expression of
their regulator-encoded gene (ORF6/pgp4) and observed a slight decrease of expression
(~1.4-fold) in the CT135-negative strain. Thus, we hypothesize that the down-regulation of
those genes might have been mediated by pgp4 underexpression. Of note, the down-regulated
genes include all members (CT619, CT620, CT621, CT711, and CT712) except CT621 of a
family of chlamydial T3S substrates characterized by a domain of unknown function (DUF582
proteins) that are believed to target nuclear cell functions [115, 125]. The highly down-
regulated non-coding small RNA (sRNA) (located between CT080 and CT082, and previously
designated ctrR0332 in the L2b/UCH-1 strain) (Table 1) was previously found to be overrepre-
sented in EBs, which is consistent with the profile found for the majority of the affected tran-
scripts [126]. Noteworthy, we observed only one differentially expressed gene (CT377/ltuA) in
the control experiment with the Ia/CS190/96 strain. This result suggests that the short-term
laboratory propagation of C. trachomatis does not substantially change gene expression in
absence of genomic alterations.
Discussion
It is known that pathogens adapt to laboratory culture conditions, whereby in vitro-maintained
strains may no longer reflect the circulating isolates. On behalf of this, the use of laboratory-
passaged strains has been frequently questioned in Chlamydia research [17, 20–24]. Although
the adaptive process behind the in vivo to in vitro transition is not understood, cumulative data
have pointed out that a deep characterization of this process is mandatory, since: i) mixed-
clone populations have been found in multiple culture stocks from both C. trachomatis and C.
muridarum strains, with clones displaying distinct in vivo virulence [23, 46, 127, 128]; ii) proto-
type strains have been suggested to display distinct phenotypic presentations when comparing
with recent clinical isolates, such as distinct growth-rates and/or yielded progeny [21, 129] and
in vivo infectivity capacities [20]; iii) in vitro passage selected for C.muridarum displaying
severely attenuated in vivo pathogenicity [16]; iv) clones with frameshift mutations in the C.
trachomatis virulence gene CT135 (or in the C.muridarum homolog TC_0412) have been
detected in several cultured populations [15, 17, 23, 46, 48, 127, 128, 130, 131]; and v) the use
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Table 1. Genes and a non-coding RNA found to be down-regulated in the serovar D CT135-negative strain.
locus a, b log2[fold change D/CT135(+) /
D/CT135(-)] c
Putative role / experimental evidence
sRNA d -3,274 Abundant non-coding RNAs differentially expressed in EBs and RBs [126].
CT082 e -3,153 T3S substrate [99, 165]. Role in host cell invasion and infectivity? [126].
CT814.1 -3,139 Putative Inc [33]. Role in host cell invasion and infectivity? [126].
CT814 -3,118 Role in host cell invasion and infectivity? [126].
CT635 -2,913 —
CT579/copD f -2,880 T3S translocation pore component (CopD) [117]. Role in host cell invasion and infectivity? [126].
CT578/copB f -2,825 T3S translocation pore component (CopB) [117]. Role in host cell invasion and infectivity? [126].
CT576/scc2 f -2,762 T3S chaperone Scc2 [116]. Role in host cell invasion and infectivity? [126].
CT577 f -2,693 Role in host cell invasion and infectivity? [126].
CT005 -2,591 Putative Inc [166]. Putative CPAF substrate [119]. Role in host cell invasion and infectivity? [126].
CT080/ltuB -2,438 Late transcription unit B protein [167]. Role in host cell invasion and infectivity? [126].
CT444/omcA f -2,348 Cysteine-rich outer membrane protein. Role in host cell invasion and infectivity? [126].
CT443/omcB f -2,214 Cysteine-rich outer membrane protein [107]. Adhesin [107, 108]. Role in host cell invasion and
infectivity? [126]. Putative CPAF substrate [118].
CT848 f -2,180 Putative T3S substrate [38]. Role in infectivity in C. muridarum? [127].
CT456/tarp -2,162 Translocated actin-recruiting phosphoprotein (TARP) / early T3S effector prepackaged into EBs [110].
Involved in host cell invasion [112]. Putative CPAF substrate [119].
CT875/tepP -2,152 Translocated early phosphoprotein (TepP) / early T3S effector involved in host cell invasion [109].
Role in host cell invasion and infectivity? [126].
CT694 f -2,140 Early T3S effector (prepackaged into EBs) involved in host cell invasion [111]. Putative CPAF
substrate [119].
(CT622) -2,120 Effector [168]. Putative plasmid-related virulence protein [51]. Role in host cell invasion and
infectivity? [126].
CT847 f -2,108 T3S effector putatively involved in the modulation of the cell cycle [113].
CT181 -2,093 Role in host cell invasion and infectivity? [126].
CT046/hctB -2,090 Histone-like protein 2. Mediate the DNA condensation that is characteristic of EBs [169].
CT849 f -2,017 T3S substrate [114]. Implicated in C. muridarum adherence to host cells [16].
CT620 -1,925 T3S effector (DUF582 family) believed to target nuclear functions [115, 125]
CT392/yprS -1,807 —
CT619 -1,738 T3S effector (DUF582 family) believed to target nuclear functions [115, 125].
(CT798/glgA) -1,736 Glycogen synthase. Plasmid-related virulence protein [51]. Effector [170].
(CT051) f -1,670 Plasmid-related virulence protein [51]. Pmp-like protein [166, 171].
CT441/Tsp -1,651 Effector. Tail-speciﬁc protease. Subversion of host cell functions by preventing the host NF-κB
activation [121, 122, 124].
CT868/
ChlaDub1
-1,648 Effector with deubiquitinating and deneddylating activity (protease) [172]. Subversion of host cell
functions by suppressing the NF-κB activation [123].
CT356/yyaL -1,631 Thioredoxin domain-containing protein [96]. Role in host cell invasion and infectivity? [126].
CT695 f -1,623 Early putative T3S effector prepackaged into EBs [111]. Putative CPAF substrate [120].
CT288 -1,619 Putative Inc [173]. T3S substrate [38]. Role in host cell invasion and infectivity? [126]. Putative CPAF
substrate [119].
(CT565) -1,572 Putative Inc [33]. Putative plasmid-related virulence protein [174].
CT546 -1,542 Predicted outer membrane protein [175].
CT712 f -1,525 Putative T3S effector (DUF582 family) believed to target nuclear functions [115, 125]. Putatively
packaged into EBs [111].
CT365 -1,459 Putative Inc [33]. T3S substrate [109]. Role in host cell invasion and infectivity? [126].
(CT702) -1,441 Putative plasmid-related virulence protein [51, 174].
CT214 -1,435 Putative Inc [165]. Role in host cell invasion and infectivity? [126].
CT711 f -1,334 Putative T3S effector (DUF582 family) believed to target nuclear functions [115, 125].
(Continued)
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Table 1. (Continued)
locus a, b log2[fold change D/CT135(+) /
D/CT135(-)] c
Putative role / experimental evidence
(CT049) f -1,325 Pmp-like protein secreted into the inclusion lumen [166, 171]. Putative plasmid-related virulence
protein [51].
CT837 -1,300 —
CT052/
hemN_1
-1,275 Coproporphyrinogen III oxidase [77].
(CT144) f, g -1,244 T3S substrate [114]. Putative plasmid-related virulence protein [51].
(CT142) f, g -1,180 T3S effector [114]. Putative plasmid-related virulence protein [51].
CT372/oprB -1,155 Outer membrane protein with a carbohydrate-selective porin (OprB) [176].
(CT050) f -1,125 Pmp-like protein secreted into the inclusion lumen [166, 171]. Putative plasmid-related virulence
protein [51].
CT564/yysT -1,114 T3SS Integral membrane structural protein (Yop proteins translocation protein T) [177].
CT735/
dagA_2
-1,037 Na(+)-linked D-alanine glycine permease [77].
CT659 -1,010 Predicted RNA binding protein [67]. Role in host cell invasion and infectivity? [126].
a Loci nomenclature and numbering refer essentially to the annotated genome from the D/UW3 strain (GenBank accession number NC_000117).
b Loci in bold are potentially down-regulated on behalf of the CT135 loss. Non-bold loci (also in parentheses) were previously found to be transcriptionally
regulated by the plasmid (namely by the plasmid-encoded protein Pgp4) [51, 174]. In the present study, the down-regulation of this latter set of genes may
be associated with Pgp4 as it was found to display lower expression levels in the D/CS637/11 CT135-negative population.
cAdjusted P-values < 0.05 and a fold-change cutoff > 2. Genes are ordered according the magnitude of differential expression.
d Refers to the previously identiﬁed sRNA ctrR0332 [126] that actually comprehends two sRNAs (likely processed from a larger transcript). In the D/UW-3
annotation, it is located inside a non-existing but previously annotated ORF (CT081). Both sRNA were similarly down-regulated.
e CT082 was suggested to be up-regulated in the pgp4 knockout mutants [51]. As in the present study it was found to be strongly down-regulated even
with a slight pgp4 expression decrease, we assumed this result as a consequence of CT135 loss.
f These genes are likely expressed in the same transcriptional unit as other down-regulated contiguous genes [also marked].
g Although it is believed that the CT143 gene is coordinately expressed with the ﬂanking genes CT142 and CT144 [114], the obtained differential
expression value was slightly below the cutoff.
doi:10.1371/journal.pone.0133420.t001
Fig 6. Comparative analysis of global gene expression (RNA-seq) between D/CT135-positive and D/CT135-negative populations. Panels A-B.
Comparison of gene expression between biological replicates for the D/CT135-positive (A) and D/CT135-negative (B) populations. Pearson correlation
coefficients are shown. Panel C. Comparison of gene expression between the D/CT135-negative and D/CT135-positive populations. The red points mark
genes and the non-coding RNA for which the fold change of expression exceeds two-fold and the FDR-corrected P-values were below 0.05. For panels A to
C, axes are log10-transformed normalized expression levels (FPKM). Panel D. Volcano plot of –log2 fold change (D/CT135-positive versusD/
CT135-negative) versus –log10 adjusted P-values. In order to better fit the scale to data, corrected P-values10−3 were set as 10−3. Points in red indicate
genes and the non-coding RNA for which the fold change of expression exceeds two-fold and the FDR-corrected P-values were below 0.05.
doi:10.1371/journal.pone.0133420.g006
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of cell-culture propagation in Chlamydia research will expectedly be boosted due to the
recent development of transformation and gene knockout experiments in Chlamydia [48–52,
132–135].
In the present study, we specifically aimed to assess the genomic and transcriptomic dynam-
ics of C. trachomatis after its introduction in culture. As the experimental design of the present
study mirrored the typical culture techniques, i.e., assisted bacterial entry and exit (by centrifu-
gation and sonication, respectively), which discards the selective pressure underlying these
steps, no discussion will be performed about evolutionary adaptation targeting specifically the
bacterial attachment and host-cell lysis. This would require a study with different design and
goals [16]. We observed a dynamics of mutation fixation for this obligate intracellular bacte-
rium that clearly fits the typical scenario of adaptive evolution seen in similar experiments in
extracellular bacteria [1, 6]. The most frequently observed events were inactivating mutations
followed by non-synonymous mutations (none of the emergent mutations in ORFs were syn-
onymous), and the mutant clones progressively rose in frequency in the population, clearly
supporting that mutations were beneficial (Fig 2). In general, our results show an adaptive sce-
nario underlying the in vivo to in vitro transition for epithelial-genital strains that seems to be
essentially marked by two major stages within different time-frames: i) a rapid and parallel evo-
lutionary loss of the virulence gene CT135; and ii) a later inactivation of the porin PorB
(encoded by the gene CT713/porB), which may be a result of a metabolic adaptation to the car-
bon source (glutamate instead of 2-oxoglutarate). Regarding the latter, it is intriguing why not
all strains were affected, which we speculate to be a matter of time-scale. Future experiments
involving the switch between glutamate and 2-oxoglutarate coupled with the analyses of the
population dynamics will certainly dissect this hypothesis. These results provide an explanation
to the enigmatic emergence of both CT135-null [15, 46, 48, 131] and porB-null mutants [136]
in in vitro populations. Notably, CT135-negative clones rapidly outcompeted CT135-positive
clones, suggesting a strong selective force against CT135 functionality. Although we cannot
exclude that inter-clone recombination may have also contributed to this notable frequency
increase, values of this magnitude were only previously observed under strong selective pres-
sures with antichlamydial compounds [137].
CT135 encodes a putative Inc [33] that contains a T3S signal recognized by heterologous
bacteria [32], but whose function is unknown. We found that CT135 may be a direct or indirect
virulence regulator, as its genetic loss together with the partial deletion of the two flanking
genes implicated a down-regulation of multiple genes, where more than 30 have been previ-
ously associated with C. trachomatis virulence properties (Table 1). We hypothesize that the
down-regulation of virulence genes constitutes the mechanism behind the observation that
CT135-null mutants showed attenuated in vivo infections in mice [46, 47]. In support of this,
an interesting recent study from Ramsey’s group [17] showed that when mice were inoculated
with C.muridarum population displaying a mixture of positive and negative clones of
TC_0412 (CT135 homolog), the former shift to predominance. Although it is believed that
CT135 is an Inc protein, its location in the inclusion membrane was never demonstrated by
immunofluorescence microscopy. Yet, CT135 is most expressed at the beginning of C. tracho-
matis life-cycle [32, 63], coincident with the formation of the inclusion membrane, and belongs
to the same operon and displays the same expression levels and profile as CT134, which also
encodes a putative Inc protein [32, 33, 46]. As the C-terminal region of CT134 was also lost in
the deletion event, we could also speculate the existence of a cooperative action involving
CT134 and CT135, where the CT135 effect would be boosted by the upstream protein.
Almost all affected virulence factors seem to be coordinately expressed at late or immedi-
ately early stages of C. trachomatis life-cycle [32, 62, 66, 67, 114, 126], suggesting their packag-
ing into EBs for subsequent rounds of infection. Curiously, some of them were previously
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shown to be transcriptionally regulated by the well-described EUO (e.g., CT443/omcB, CT080/
ltuB, CT441/Tsp and CT576/scc2), which similarly to CT135 is also an early protein [138, 139],
or by the plasmid Pgp4 (e.g., CT049-CT051, CT142-CT144, CT622 and CT798/glgA) [51].
Whereas CT446/euo revealed no changes in expression, the slight lower expression of pgp4
may justify the detected down-regulation of Pgp4-targets. This latter observation leaves open
the possibility that the attenuation of C. trachomatis virulence in vitromay occur by more than
one mechanism (such as genomic inactivation of CT135 and/or down-regulation of the viru-
lence regulator Pgp4), which potentially take place in a cumulative or differential fashion
depending on the strain. Future transcriptional analyses of other in vitro passaged strains,
namely CT135-unaltered strains and strain with an extent passaging time-scale, will certainly
be important to confirm this hypothesis.
The most down-regulated locus (about 10-fold) was the previously described sRNA
ctrR0332 [126]. Although increasing data have shown that the expression of sRNAs may be
determinant for virulence in both extracellular [140] and intracellular bacterial pathogens
[141] and, in C. trachomatis, one sRNA (lhtA) was found to control the timing of RB to EB
transition [142, 143], the specific role of the sRNA ctrR0332 on C. trachomatis virulence cannot
be determined yet. However, it is tempting to hypothesize that it may regulate CT135 (for
instance, by controlling its mRNA stability), whose loss would render the sRNA dispensability.
Collectively, all these data indicate that the control of C. trachomatis virulence at the stage
where EBs are loaded with virulence determinants is likely multi-factorial.
The scenario of the rapid loss of CT135 in the transition from in vivo to in vitro raises rele-
vant issues concerning studies where intensive laboratory propagation is necessary, such as
mutagenesis, transformation and/or drug testing. In fact, these may enhance the selection of
CT135-negative mutants, where a single inactivating event may have a downstream strong
impact on the virulence and pathogenicity of the strains, introducing bias when interpreting
data on the course of their use. For example, the loss of virulence after in vitro propagation is
well-documented for other important human pathogens, such asMycobacterium tuberculosis
[10], Staphylococcus aureus [12], Coxiella burnetii [11] and Campylobacter jejuni [144]. There-
fore, it seems important that researchers performing studies with laboratory-propagated C. tra-
chomatis epithelial-genital strains confirm the integrity of CT135 in selected clones. This issue
is also raised when working with C.muridarum, as the interpretation of the results from recent
studies searching for targets of antibiotic resistance [130] or evaluating pathogenicity in vivo
[16] was complicated by the presence of frameshift mutation in CT135-homolog. On the other
hand, this issue can be overcome if complementation assays are applied to study the genetic
linkage between a mutant allele and the expected phenotype.
One intriguing result was the observation that CT135 inactivation occurred for all epithe-
lial-genital strains (regardless of both their genetic backbone and the clinical prevalence of
their representative serovars), but not for strains with different tissue tropism (LGV and ocular
strains). Considering that C. trachomatis is likely undergoing a directional evolution towards
niche-specific adaptation to each infected tissue—ocular conjunctivae, genital mucosa and
lymph nodes [58, 74, 145, 146], one might speculate that CT135 may be a direct or indirect
determinant of tissue tropism, as suggested for other C. trachomatis loci (e.g., the cytotoxin
gene and the tryptophan operon) [82, 147, 148]. Several lines of evidence sustain that the LGV
strains evolve to retain the CT135 activity in vitro: i) the passaging of the LGV-proctitis associ-
ated clinical isolate do not lead to the CT135 disruption (Fig 2); ii) CT135-null mutants did not
arise even when the historical LGV prototype strain (L2/434/Bu) was continuously propagated
in HeLa cells during over one year [15]; and iii) no CT135 polymorphisms were found within
the population of any prototype strain from different LGV serovars (L1, L2 and L3) [46].
Regarding the ocular strain that we have used (C/TW-3), we observed a scenario where a sub-
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population of CT135-null clones evolved to extinction (Fig 2 and S3 Table), which is enigmatic
since the CT135 was already found to be disrupted in several annotated genomes of ocular
strains [48, 58, 149, 150]. Considering all these observations, and although the HeLa cell line is
one of the most commonly used for culturing C. trachomatis, we wonder if a similar scenario is
obtained by propagating LGV and ocular strains in tropism-related cell-lines, such as mono-
cytic or conjunctival cell lines, respectively. CT135 transcripts have been found to be more
labile for the LGV strain (Fig 5), but this does not directly mean that CT135 does not contrib-
ute to the ability of C. trachomatis LGV strains to infect macrophages and disseminate to
lymph nodes. In fact, the CT135 protein sequence has five LGV-specific amino acids (data not
shown), and was previously found to be among a pool of genes likely involved in phenotypic
differences among LGV strains [54].
The growth rate of all laboratory evolving populations increased relative to the ancestral
populations (leading to shorter life-cycles), reflecting a gradual Darwinian fitness improvement
over time (Fig 4). Although we cannot attribute the life-cycle shortening to the inactivation of
CT135 (since the ocular and the L2b strains also improved their fitness, and other mutations
arose), it is noteworthy that in vivo studies also suggested that CT135 operates in sustaining a
more persistent or chronic infections in the female mouse genital model [47]. Other fixed
mutations (Fig 2 and S3 Table) have also the potential for altering the bacterial fitness likely by
affecting: i) the cell division (mutation in CT645); ii) the nutrient acquisition/processing
(mutations in CT205/pfkA_1, CT257 and CT713/porB); or iii) global regulatory mechanisms,
such as DNA supercoiling (mutation in CT189/gyrA_1). Finally, despite most gene targets
showed no parallelism across strains (at least for the time-scale evaluated), we cannot discard
that these mutational events may be related to the CT135 loss [either functionally or genetically
(e.g., hitchhiking)].
In the present experimental evolution study, we also found genetic features potentially
underlying phase variation mechanisms in C. trachomatis. Phase variation may be driven by
reversible alterations in the genotype that causes either frameshift or mutations in non-coding
regions impacting gene expression (Fig 1D), and has been associated with genes involved in
host-pathogen interactions [151, 152]. Within Chlamydiaceae, to our knowledge, phase varia-
tion mediated by homopolymeric tracts was only hypothesized to occur in C. pneumoniae,
affecting members of the paralogous gene families Pmps [153, 154] and Cpn 1054 [155]. Here,
we detected variable homopolymeric tracts that have the potential to modulate the functional-
ity of genes encoding proteins likely involved in C. trachomatis pathogenesis: a poly(G) tract
within CT166 (encodes the cytotoxin [81]) and a poly(A) tract in the promoter region of
CT533/lpxC [encoding a critical enzyme in the biosynthesis of lipid A of lipopolysaccharide
(LPS) [76]] (Fig 1). Regarding the cytotoxin, variable ‘G’ counts yielding an ON/OFF protein
(also present in genomes obtained directly from clinical swabs) suggest the putative existence
of cytotoxin-mediated phenotypic diversity within in vivo C. trachomatis populations of epi-
thelial-genital strains. Still, we wondered if the frameshift mutation in the poly(G) tract could
lead to the production of an alternative shorter protein (still including the UDP-glucose bind-
ing and glycosiltransferase domains), since the translation could eventually be reinitiated at an
alternative putative start codon at position 93 (as frequently annotated in C. trachomatis
genomes deposited in GenBank). However, RNA-seq analyses were not helpful to elucidate
this subject as no transcripts were detected (data not shown), hampering the clarification of the
two hypotheses. Besides its known activity as an effector in disassembling the host cytoskeleton
upon bacterial invasion [81, 83, 84] and it is putative role in subversion of other cellular func-
tions [82], the chlamydial cytotoxin was proposed to account for the resistance to the anti-
bacterial effect of IFN-γ [94, 156–158]. In particular, the C. trachomatis cytotoxin was hypothe-
sized to target human guanylate binding proteins (hGBPs) that are potentiators of the IFN-γ
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activity (i.e., depletion of the essential amino acid tryptophan) [159, 160]. Therefore, although
epithelial-genital strains are capable of using indole for tryptophan biosynthesis [147], we
hypothesize that this putative phase variation mechanism may contribute for the quick adapta-
tion of C. trachomatis to changes in the tryptophan availability by targeting IFN-γ-inducible
hGBPs. Concerning the poly(A) tract upstream from CT533/lpxC, we observed an increase in
frequency of clones carrying dissimilar base counts (Fig 1A and S3 Table), supporting selective
advantage. It affects the highly conserved length of the spacer region between the predicted -35
and -10 ‘TATA’ boxes (Fig 1B and 1D), which might alter the binding of the RNA polymerase
to the promoter, and thus, the gene expression. We also found this polymorphism in GenBank
annotated genomes. Curiously, in a pioneer study back to 1990s [161], it was proposed that the
Chlamydia LPS is phase-variable, since LPS phenotypic variation was found within a popula-
tion in tissue culture. In other bacteria, including intracellular organisms, phase variation
mechanisms affecting the LPS biosynthesis are well-documented to be associated with anti-
genic variation [162]. For instance, it was demonstrated that a phase variation-mediated anti-
genic shift of LPS modulates the ability of Francisella tularensis to grow within macrophages
[163]. In this regard, a phase variation mechanism targeting the CT533/lpxC in C. trachomatis
may control the biosynthesis of lipid A, and ultimately LPS antigenic variation mechanisms for
evading the host immune system. Although it was previously demonstrated that C. trachomatis
fails to generate infectious EBs in the presence of LpxC inhibitors [76], putative alterations in
the expression of CT533/lpxCmediated by the differential length of the promoter spacing did
not seem to hamper the progression of chlamydial infection as the progeny of serovar E strain
was not affected. Curiously, we noted that the CT134-CT135 transcript has also a poly(T)
located between the TSS and the start codon of CT134 (Fig 1D). Although no assumption can
be done on its phenotypic impact, a GenBank search revealed a rather intriguing profile of
nine, eight and seven ‘T’ counts for most LGV strains, ocular and epithelial-genital strains,
respectively. Globally, although the existence of heterogeneity within homopolymeric tracts in
C. trachomatis populations seem to be more common than previously expected and to poten-
tially modulate important bacterial functions, their role in mediating phase variable pheno-
types with impact on pathogenesis still needs experimental confirmation. In this regard,
phenotypic assays coupled with genetic reversibility of phase variation will soon be tested.
As concluding remarks, our study focused on the C. trachomatis in vivo to in vitro transition
reveals not yet identified putative phase variation mechanisms targeting genes involved in
pathogenesis, and also potentially contributes to the clarification of the molecular basis under-
lying the CT135-mediated virulence. CT135 may be a master player in pre-loading EBs with
virulence effectors required for the invasion and subversion of epithelial cells. More, as the
length of time in the in vitro culture is a predisposing factor that contributes to the loss of this
virulence gene in epithelial-genital strains, this may constitute an issue as studies demanding
culture propagation might enhance the selection of CT135-negative mutants, originating less
virulent strains. Thus, restricting laboratory propagation to minimal passages, evaluating the
status of the CT135 genotype and performing complementation of mutants might constitute
good premises towards both a better interpretation of phenotypic data and inter-laboratory
comparisons.
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